2026 Annual General Meeting notification

OXB

2026 Annual General Meeting notification

Oxford, UK - 30 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2025 Annual report and accounts are being mailed to shareholders today. These documents are also available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with UK Listing rule 6.4.1R, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism. The Company intends to hold its AGM on 7 May 2026 at its offices at Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

-Ends- 

Enquiries:

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: [email protected]

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.